{
  "paper_metadata": {
    "pmid": "35914747",
    "title": "Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data",
    "extraction_summary": "Extracted information on BRCA2 variants, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": null,
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 8,
        "demographics": "female, age range not specified",
        "phenotype": "breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 8,
        "affected_count": 4,
        "unaffected_count": 4,
        "uncertain_count": null,
        "penetrance_percentage": 50.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "A patient with a BRCA2 p.I1859fs mutation received olaparib at her own expense."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "A patient with a BRCA2 c.8633-2A>T mutation tested negative for germline BRCA mutations and received olaparib as part of a clinical trial."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "Another patient with a BRCA1 p.K608fs mutation entered the clinical trial and received olaparib."
        },
        {
          "individual_id": "P4",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "A patient with a BRCA2 p.R2494 mutation was enrolled in a phase 1 clinical trial of a PARP/TNK inhibitor."
        },
        {
          "individual_id": "P5",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "not specified",
          "evidence_sentence": "The decision to enroll in the clinical trial was based on the NGS results."
        },
        {
          "individual_id": "P6",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "not specified",
          "evidence_sentence": "The patient did not undergo germline BRCA testing."
        },
        {
          "individual_id": "P7",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "not specified",
          "evidence_sentence": "The patient remained in the MP-guided treatment group."
        },
        {
          "individual_id": "P8",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "not specified",
          "evidence_sentence": "The patient did not undergo germline BRCA testing."
        }
      ],
      "functional_data": {
        "summary": "BRCA2 mutations are associated with breast cancer susceptibility.",
        "assays": [
          "NGS testing",
          "germline BRCA testing"
        ]
      },
      "segregation_data": "Segregation with disease in families not explicitly mentioned.",
      "population_frequency": null,
      "evidence_level": "moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The exact nature of the BRCA2 variants was not specified.",
      "key_quotes": [
        "Among the 81 patients with advanced breast cancer with targetable genomic alterations, 6 (7.4%) received MP-guided treatment.",
        "Of the 4 patients with BRCA mutations, one with a BRCA2 p.I1859fs mutation received olaparib at her own expense."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "Extracted data was primarily from the results section and individual patient descriptions."
  }
}